Modern Pediatrics. Ukraine. (2023). 8(136): 67-78. doi: 10.15574/SP.2023.136.67
Bogomolets O. V.^1,2,3, Selyuk O. V.¹, Bogomolets K. P.³, Bogomolets-Sheremetieva S. O.^3,4
1Ukrainian Military Medical Academy, Kyiv
²Academy of Silesia, Katowice, Poland
³Dr. Bogomolets’ Institute of Dermatology and Cosmetology, Kyiv, Ukraine
⁴Bogomolets National Medical University, Kyiv, Ukraine

For citation: Bogomolets OV, Selyuk OV, Bogomolets KP, Bogomolets-Sheremetieva SO. (2023). Treatment of infantile hemangioma with topical β-blockers in pediatric practice: a review of the literature. Modern Pediatrics. Ukraine. 8(136): 67-78. doi: 10.15574/SP.2023.136.67.
Article received: Sep 28, 2023. Accepted for publication: Dec 12, 2023.

The purpose of this review is to acquaint the audience with the benefits of infantile hemangioma  (IH) treatment with local β-blockers, which are safe for the child, allow for the complete cure of hemangiomas without surgery, complications, scars, and cosmetic defects, and have practically no systemic side effects. We aimed to analyze the effectiveness and limitations of the use of local β-blockers, to show the possibility and expediency of IH management in pediatric practice, and to demonstrate that the goal of therapy is not the treatment of complications, but the prevention of their occurrence and complete resolution of the hemangioma without surgical intervention.
The use of topical β-blockers, such as timolol gel or solution, provides a non-surgical, non-invasive treatment option for IH, minimizing the systemic exposure and possible side effects associated with oral β-blockers. Local treatment is best started before the age of 2 months – at an early stage, when IHs are small in size, potentially preventing the need for more invasive treatment methods.
Topical use is associated with a lower risk of systemic side effects, such as hypotension or bradycardia, that can occur with oral β-blockers. Topical treatment can be applied at home, which can be more convenient for parents and caregivers, and also increases the opportunity for treatment and follow-up by pediatricians. In case of natural disasters or military operations, treatment can be done remotely using teledermatology.
The effectiveness of local β-blockers mostly depends on the age at which treatment was started: the earlier it was started, the higher the effectiveness. Treatment of complicated IH with deep soft tissue, mucosal, or airway involvement usually requires a combination of systemic propranolol and topical β-blockers or other interventions such as laser therapy.
The choice of treatment should be selected individually according to the degree of risk of IH, its size, localization, child's age, weight, and other parameters in each clinical case β-adrenoblockers are the most modern, effective, non-surgical, and safe method of treating IH, they can be used both for systemic and local application. IH can be successfully treated by pediatricians and dermatologists.
No conflict of interests was declared by the authors.
Keywords: infantile hemangioma, hemangioma treatment, local β-blockers, timolol.

REFERENCE

1. Almebayadh M. (2020). Successful treatment of ulcerated infantile IH with brimonidine-timolol cream: 2 cases report and review of the literature. J. Dermatolog. Treat. 31; 4: 433-434. https://doi.org/10.1080/09546634.2019.1603991; PMid:30973791

2. Anderson KR, Schoch JJ, Lohse CM et al. (2016). Increasing incidence of infantile IHs (IH) over the past 35 years: Correlation with decreasing gestational age at birth and birth weight. J. Am. Acad. Dermatol. 74; 1: 120-126. https://doi.org/10.1016/j.jaad.2015.08.024; PMid:26494585 PMCid:PMC4994883

3. Chakkittakandiyil A, Phillips R, Frieden U et al. (2012). Timolol maleate 0.5% or 0.1% gel-forming solution for infantile IHs: a retrospective, multicenter, cohort study. Pediatr. Dermatol. 29; 1: 28-31. https://doi.org/10.1111/j.1525-1470.2011.01664.x; PMid:22150436

4. Chan H, McKay C, Adams S, Wargon O. (2013). RCT of timolol maleate gel for superficial infantile IHs in 5- to 24-week-olds. Pediatrics. 31; 6: e1739-e1747. https://doi.org/10.1542/peds.2012-3828; PMid:23650294

5. Chang LC, Haggstrom AN, Drolet BA et al. (2008). Growth characteristics of infantile IHs: implications for management. Pediatrics. 122; 2: 360-367. https://doi.org/10.1542/peds.2007-2767; PMid:18676554

6. Cheng CE, Friedlander SF. (2016). Infantile IHs, complications, and treatments. Semin Cutan Med Surg. 35(3): 108-116. https://doi.org/10.12788/j.sder.2016.050; PMid:27607318

7. Gan LQ, Wang H, Ni SL, Tan CH. (2018) A prospective study of topical carteolol therapy in Chinese infants with superficial infantile IH. Pediatr. Dermatol. 35; 1: 121-125. https://doi.org/10.1111/pde.13361; PMid:29243341

8. Hagen R, Ghareeb E, Jalali O, Zinn Z. (2018). Infantile IHs: what have we learned from propranolol? Curr. Opin. Pediatr. 30; 4: 499-504. https://doi.org/10.1097/MOP.0000000000000650; PMid:29846253

9. Hogeling M, Adams S, Wargon O. (2011). A randomized controlled trial of propranolol for infantile IHs. Pediatrics. 128; 2: e259-e266. https://doi.org/10.1542/peds.2010-0029; PMid:21788220

10. Itinteang T, Brasch HD, Tan ST, Day DJ. (2011). Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for propranolol-induced accelerated involution. J. Plast. Reconstr. Aesthet. Surg. 64; 6: 759-765. https://doi.org/10.1016/j.bjps.2010.08.039; PMid:20870476

11. Itinteang T, Withers AH, Davis PF, Tan ST. (2014). Biology of infantile IH. Front Surg. 1; 38. https://doi.org/10.3389/fsurg.2014.00038; PMid:25593962 PMCid:PMC4286974

12. Ji Y, Chen S, Wang Q et al. (2018). Intolerable side effects during propranolol therapy for infantile IH: frequency, risk factors, and management. Sci Rep. 8(1): 4264. https://doi.org/10.1038/s41598-018-22787-8; PMid:29523832 PMCid:PMC5844887

13. Jong SDe, Itinteang T, Withers AH et al. (2016). Does hypoxia play a role in infantile IH? Arch. Dermatol. Res. 308; 4: 219-227. https://doi.org/10.1007/s00403-016-1635-x; PMid:26940670

14. Katona G, Csákányi Z, Gács E et al. (2012). Propranolol for infantile haemangioma: striking effect in the first weeks. Int. J. Pediatr. Otorhinolaryngol. 76; 12: 1746-1750. https://doi.org/10.1016/j.ijporl.2012.08.014; PMid:22944359

15. Kilcline C, Frieden IJ. (2008). Infantile IHs: how common are they? A systematic review of the medical literature. Pediatric Dermatology. 25; 2: 168-173. https://doi.org/10.1111/j.1525-1470.2008.00626.x; PMid:18429772

16. Kim JH, Lam JM. (2021). Pediatrics: how to manage infantile haemangioma. Drugs Context. 6; 10: 2020-12-6. https://doi.org/10.7573/dic.2020-12-6 PMid:33889196 PMCid:PMC8029639

17. Kovačević M, Lukinović Škudar V, Maričić G et al. (2014). Topical propranolol cream in the treatment of superficial infantile IHs: a literature review and 4 years of clinical experience. Acta Dermatovenero.l Alp. Pannonica Adriat. 23; 4: 75-78. https://doi.org/10.15570/actaapa.2014.18; PMid:25527040

18. Kurlak LO, Mistry HD, Cindrova-Davies T et al. (2016). The human placental renin-angiotensin system in normotensive and pre-eclamptic pregnancies at high altitude and after acute hypoxia-reoxygenation insult. J. Physiol. 594; 5: 1327-1340. https://doi.org/10.1113/JP271045; PMid:26574162 PMCid:PMC4771780

19. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T et al. (2008). Propranolol for severe IHs of infancy. N. Engl. J. Med. 358; 24: 2649-2651. https://doi.org/10.1056/NEJMc0708819; PMid:18550886

20. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J et al. (2015). A randomized, controlled trial of oral propranolol in infantile IH. N. Engl. J. Med. 372; 8: 735-246.

21. Li G, Xu DP, Tong S et al. (2016). Oral propranolol with topical timolol maleate therapy for mixed infantile IHs in oral and maxillofacial regions. J. Craniofac. Surg. 27; 1: 56-60. https://doi.org/10.1097/SCS.0000000000002221; PMid:26716547

22. Lo K, Mihm M, Fay A. (2009). Current theories on the pathogenesis of infantile IH. Semin. Ophthalmol. 24; 3: 172-177. https://doi.org/10.1080/08820530902805438; PMid:19437354

23. Mashiah J, Kutz A, Rabia SH et al. (2017). Assessment of the effectiveness of topical propranolol 4% gel for infantile IHs. Int. J. Dermatol. 56; 2: 148-153. https://doi.org/10.1111/ijd.13517; PMid:28074521

24. Mulliken JB, Glowacki J. (1982). IHs and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast. Reconstr. Surg. 69; 3: 412-422. https://doi.org/10.1097/00006534-198203000-00003

25. Muñoz-Garza FZ, Ríos M, Roé-Crespo E et al. (2021). Efficacy and safety of topical timolol for the treatment of infantile IH in the early proliferative stage: A randomized clinical trial. JAMA Dermatol. 157; 5: 583-587. https://doi.org/10.1001/jamadermatol.2021.0596; PMid:33825828 PMCid:PMC8027942

26. Ng ZY, Kang GC, Chang CS, Por YC. (2016) Efficacy of topical timolol as primary monotherapy in cutaneous facial infantile IHs. J. Craniofac. Surg. 27; 6: e516-e520. https://doi.org/10.1097/SCS.0000000000002849; PMid:27428916

27. Oranje AP, Janmohamed SR, Madern GC, De Laat PC. (2011). Treatment of small superficial haemangioma with timolol 0.5% ophthalmic solution: a series of 20 cases. Dermatology. 223; 4: 330-334. https://doi.org/10.1159/000334778; PMid:22179543

28. Ovadia SA, Landy DC, Cohen ER et al. (2015). Local administration of β-blockers for infantile IHs: a systematic review and meta-analysis. Ann. Plast. Surg. 74; 2: 256-262. https://doi.org/10.1097/SAP.0000000000000390; PMid:25590249

29. Painter SL Hildebrand GD. (2016). Review of topical beta blockers as a treatment for infantile IHs. Surv. Ophthalmol. 61; 1: 51-58. https://doi.org/10.1016/j.survophthal.2015.08.006; PMid:26408055

30. Prasad A, Sinha AK, Kumar B et al. (2019). Individualized dosing of oral propranolol for treatment of infantile IH: a prospective study. Pan. Afr. Med. J. 32; 155.

31. Price A, Rai S, Mcleod RWJ et al. (2018). Topical propranolol for infantile haemangiomas: a systematic review. J. Eur. Acad. Dermatol. Venereol. 32; 12: 2083-2089. https://doi.org/10.1111/jdv.14963; PMid:29569772

32. Püttgen K, Lucky A, Adams D. (2016). Topical timolol maleate treatment of infantile IHs. Pediatrics. 138 (3): e20160355. https://doi.org/10.1542/peds.2016-0355; PMid:27527799

33. Ritter MR, Butschek RA, Friedlander M, Friedlander SF. (2007). Pathogenesis of infantile haemangioma: new molecular and cellular insights. Expert Rev. Mol. Med. 9; 32: 1-19. https://doi.org/10.1017/S146239940700052X; PMid:18045510

34. Smith CJF, Friedlander SF, Guma M, et al. (2017). Infantile IHs: An updated review on risk factors, pathogenesis, and treatment. Birth Defects Res. 109; 11: 809-815. https://doi.org/10.1002/bdr2.1023; PMid:28402073 PMCid:PMC5839165

35. Tan ST, Itinteang T, Day DJ et al. (2012). Treatment of infantile haemangioma with captopril. Br. J. Dermatol. 167; 3: 619-624. https://doi.org/10.1111/j.1365-2133.2012.11016.x; PMid:22533490

36. Tang YJ, Zhang ZZ, Chen SQ et al. (2015). Effect of topical propranolol gel on plasma renin, angiotensin II, and vascular endothelial growth factor in superficial infantile IHs. J. Huazhong Univ. Sci. Technolog. Med. Sci. 35; 5: 759-762. https://doi.org/10.1007/s11596-015-1503-5; PMid:26489635

37. Weibel L, Barysch MJ, Scheer HA et al. (2016). Topical timolol for infantile IHs: evidence for efficacy and degree of systemic absorption. Pediatr. Dermatol. 33; 2: 184-190. https://doi.org/10.1111/pde.12767; PMid:26840644

38. Wu HW, Wang X, Zhang L et al. (2018). Topical timolol vs. oral propranolol for the treatment of superficial infantile IHs. Front Oncol. 8: 605. https://doi.org/10.3389/fonc.2018.00605; PMid:30619747 PMCid:PMC6305365

39. Xu DP, Cao RY, Tong S et al. (2015). Topical timolol maleate for superficial infantile IHs: an observational study. J. Oral. Maxillofac. Surg. 73; 6: 1089-1094. https://doi.org/10.1016/j.joms.2014.12.026; PMid:25843815

40. Xu G, Lv R, Zhao Z, Huo R. (2012). Topical propranolol for treatment of superficial infantile IHs. J. Am. Acad. Dermatol. 67; 6: 1210-1213. https://doi.org/10.1016/j.jaad.2012.03.009; PMid:22516113

41. Yilmaz L, Dangoisse C, Semaille P. (2013). Infantile IH and propranolol: a therapeutic "revolution". Literature review. Rev. Med. Brux. 34; 6: 479-784.

42. Zhai YN, Song HT, Chen SQ, et al. (2013) Effect of propranolol gel on infantile IHs. Zhonghua Zheng Xing Wai Ke Za Zhi. 29; 1: 25-28.